Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vor Biopharma
Fierce Pharma
Vor Bio's surprise $4B revival deal splits investor reactions
In response to the deal, Vor's stock price more than doubled in premarket trading, while RemeGen’s stock price in Hong Kong dropped 18% Thursday.
Angus Liu
Jun 26, 2025 10:55am
Vor Bio to wind down, laying off most staff
May 8, 2025 10:50am
Vor Bio's dual stem cell, ADC shows consistent engraftment
Nov 9, 2023 4:10pm
Vor's cancer cell therapy gets on FDA's fast track
Sep 10, 2021 6:07am
J&J, Vor ally to assess bispecific and stem cell therapy in AML
Jul 9, 2021 7:50am
Vor Biopharma hits Wall Street with $177M IPO
Feb 5, 2021 3:25pm
